Janney Montgomery Scott LLC Makes New Investment in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Janney Montgomery Scott LLC purchased a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 15,250 shares of the company’s stock, valued at approximately $121,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its holdings in shares of Amneal Pharmaceuticals by 149.7% in the third quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company’s stock valued at $10,792,000 after purchasing an additional 777,568 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Amneal Pharmaceuticals by 114.1% in the third quarter. Assenagon Asset Management S.A. now owns 1,204,994 shares of the company’s stock valued at $10,026,000 after purchasing an additional 642,065 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Amneal Pharmaceuticals by 11.1% in the third quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company’s stock valued at $31,511,000 after purchasing an additional 378,136 shares in the last quarter. Polar Asset Management Partners Inc. lifted its holdings in shares of Amneal Pharmaceuticals by 122.5% in the third quarter. Polar Asset Management Partners Inc. now owns 393,000 shares of the company’s stock valued at $3,270,000 after purchasing an additional 216,400 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Amneal Pharmaceuticals by 16.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,404,883 shares of the company’s stock valued at $11,689,000 after acquiring an additional 202,863 shares during the last quarter. Institutional investors own 31.82% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on AMRX shares. StockNews.com downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 19th. Piper Sandler increased their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Insiders Place Their Bets

In other news, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $8.14, for a total value of $651,200.00. Following the completion of the transaction, the director now directly owns 1,888,886 shares in the company, valued at approximately $15,375,532.04. The trade was a 4.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 160,000 shares of company stock valued at $1,292,000 over the last ninety days. 26.56% of the stock is currently owned by insiders.

Amneal Pharmaceuticals Price Performance

NASDAQ:AMRX opened at $7.91 on Friday. The business has a fifty day simple moving average of $8.09 and a two-hundred day simple moving average of $8.25. Amneal Pharmaceuticals, Inc. has a 1 year low of $5.01 and a 1 year high of $9.48. The company has a market capitalization of $2.45 billion, a P/E ratio of -11.63 and a beta of 1.10.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.